GAtherton

Antifungal drug interactions: what patients with aspergillosis need to know

Last reviewed: April 2026

Key points

  • Antifungal medicines can interact with other medicines, including inhalers, steroid tablets, blood thinners, heart medicines, cholesterol tablets, and some over-the-counter or herbal products.
  • The azole antifungals usually interact by affecting how the liver handles medicines.
  • Amphotericin B is different: its main interaction risks are more often linked to kidneys, potassium, magnesium, and infusion-related effects.
  • This page gives an overview. It does not list every interaction.
  • For a full medicine-by-medicine check, use the BNF interaction checker or ask a pharmacist or clinician.

Why interactions matter in aspergillosis

People with aspergillosis often take more than one medicine. This may include inhalers, steroid tablets, medicines for reflux, antibiotics, pain relief, blood pressure treatment, blood thinners, cholesterol tablets, and drugs for other long-term conditions. That means medicine checks are especially important whenever an antifungal is started, stopped, or changed.

How the main antifungals differ

Most long-term interaction questions in aspergillosis involve the azole antifungals: itraconazole, voriconazole, posaconazole, and isavuconazole. These mainly interact because they affect liver enzymes, especially CYP3A4, although some also affect CYP2C9 and CYP2C19.

Amphotericin B behaves differently. Its most important risks are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines rather than classic liver-enzyme interactions.

Quick comparison table

Antifungal Main interaction pattern Typical complexity Important extra point
Itraconazole Strong enzyme-based interactions, especially CYP3A4 High Capsules and liquid are not handled by the body in the same way
Voriconazole Complex enzyme-based interactions involving several CYP pathways High More variable between patients; visual side effects and photosensitivity are well recognised
Posaconazole Mainly CYP3A4-related interactions Moderate Tablets and oral suspension are not interchangeable in the same way
Isavuconazole Mainly CYP3A4-related interactions, usually less complex than older azoles Lower to moderate Can shorten the QT interval
Amphotericin B Kidney, potassium, magnesium, and infusion-related interaction risks Different rather than simpler Formulations are not interchangeable

Individual antifungal guides

What patients should do in practice

  • Keep an up-to-date list of all medicines, including inhalers, creams, over-the-counter medicines, supplements, and herbal products.
  • Tell your doctor, nurse, pharmacist, or hospital team that you are taking an antifungal.
  • Do not start, stop, or swap medicines on your own because of something you have read online.
  • Ask specifically about new medicines, steroid changes, reflux treatment, blood thinners, cholesterol medicines, and heart medicines.

When to seek medical advice

Seek medical advice promptly if symptoms change after a medicine is started, stopped, or changed. Seek urgent help for severe bleeding, fainting, severe muscle pain, marked palpitations, rapidly worsening breathlessness, severe drowsiness, or a sudden significant decline in your health.

Important

This resource is educational. It does not replace personalised advice from your clinical team, GP, or pharmacist, and it is not a complete interaction database.

References

by GAtherton

Hydrocortisone Injection Changes in the UK: What It Means for Aspergillosis Patients

Last reviewed: March 2026
Audience: Patients, carers, and non-specialist healthcare professionals

Key points

  • A ready-to-use hydrocortisone injection (liquid solution) is no longer available in the UK.
  • Patients are now usually given a hydrocortisone injection that must be mixed before use.
  • The medication itself is unchanged, but preparation is more complex.
  • This may feel more difficult during an emergency, especially if someone is unwell or distressed.
  • Training and preparation can help reduce delays.
  • Always seek urgent medical help in a suspected emergency.

Table of contents

Overview

Hydrocortisone is a steroid hormone used as cortisol replacement in people whose bodies cannot produce enough cortisol, a condition known as adrenal insufficiency.

Some patients with aspergillosis may be affected by this change because:

  • long-term steroid use can suppress the body’s natural cortisol production
  • adrenal function may be reduced during or after treatment
  • some patients may already have adrenal insufficiency or need emergency steroid cover

In emergencies, hydrocortisone injections can be life-saving.

Why hydrocortisone matters in aspergillosis

Patients with aspergillosis may encounter adrenal-related issues for several reasons. For example, some people with allergic bronchopulmonary aspergillosis (ABPA) have needed prolonged courses of steroid treatment. Over time, this can reduce the body’s own cortisol production.

There can also be concerns about drug interactions, especially where antifungal medicines and steroid medicines affect the way the body handles hormones. Not every aspergillosis patient will be affected, but for some people this is an important part of their wider treatment plan.

If cortisol levels are too low during illness, injury, vomiting, or other physical stress, this can lead to an adrenal crisis, which is a medical emergency.

What has changed in the UK

Previously, some patients were supplied with a ready-made liquid hydrocortisone injection. This was already in solution and could be given more quickly.

This ready-to-use product is no longer available in the UK.

Most patients who need emergency hydrocortisone injection are now supplied with a preparation that includes:

  • a vial containing hydrocortisone powder
  • a liquid for mixing
  • a syringe and needle for drawing up and giving the injection

The medicine itself is still hydrocortisone and remains standard treatment. What has changed is the practical process: it now needs to be prepared before it can be injected.

Diagram: preparing hydrocortisone injection

Preparing a hydrocortisone injection (Video) : https://www.youtube.com/watch?v=NXXB3w1ADcI

What this means in practice

For many patients, this change is manageable with training and practice. However, it does change the experience of using emergency medication.

Compared with a ready-made solution, there are now more steps involved. In a calm situation, that may not seem significant. In an emergency, it can feel much harder.

This is especially relevant if the person is:

  • very unwell
  • vomiting
  • dizzy or confused
  • trying to guide a family member or carer through the process

For some patients, this could potentially cause a delay in giving the injection. That does not mean the current treatment is ineffective or unsafe, but it does mean that confidence, familiarity, and training matter even more.

Potential concerns and risks

1. More steps may mean more delay

The current injection usually has to be mixed before use. That means opening the kit, preparing the medicine, drawing it up, and then giving the injection. In an emergency, even a short delay may feel important.

2. Stress makes practical tasks harder

Patients and carers are often being asked to act quickly during a frightening situation. Even people who have previously been shown what to do may lose confidence if they rarely need to use the injection.

3. Training may vary

Not everyone receives the same level of teaching or refresher support. Some people may feel very confident. Others may feel unsure, especially if their kit has changed.

4. Aspergillosis patients may already be managing a lot

Some patients are already coping with breathlessness, fatigue, infections, multiple medicines, and complex follow-up. Adding a more complicated emergency injection process can feel like an extra burden.

It is important to keep this concern in proportion. Many patients and carers do use mixed hydrocortisone kits successfully. The key issue is not that the medicine no longer works, but that the loss of a ready-made formulation may make emergency use less straightforward.

Practical steps for patients and carers

If you have been prescribed emergency hydrocortisone, it may help to:

  • check that you know exactly which product you have been given
  • ask for a demonstration of how to prepare and inject it
  • ask for a refresher if you are not confident
  • make sure family members, carers, or trusted friends also know what to do
  • keep the emergency kit somewhere accessible and check expiry dates regularly
  • carry any steroid emergency information you have been given, such as a steroid card

These steps cannot remove all risk, but they may reduce hesitation and confusion if the injection is ever needed urgently.

Common questions

Has hydrocortisone been withdrawn completely?

No. Hydrocortisone is still widely used. The main issue is that a ready-to-use liquid injectable form is no longer available in the UK.

Is the current injection less effective?

No. The medicine remains hydrocortisone. The change is in the formulation and the preparation steps, not in the intended effect of treatment.

Why does this matter so much?

In an emergency, simple treatments are often easier to use correctly and quickly. A preparation that needs mixing may be more difficult for some patients or carers under pressure.

Does this affect every aspergillosis patient?

No. This is mainly relevant to people who have adrenal insufficiency, adrenal suppression, or a clear plan from their clinical team to keep emergency hydrocortisone available.

Should patients be worried?

Patients should not panic, but it is reasonable to recognise this as a practical concern. If you rely on emergency hydrocortisone, it is sensible to make sure you understand your current kit and feel as confident as possible using it.

When to seek medical help

Seek urgent medical help if there are symptoms suggesting a possible adrenal emergency, especially if there is:

  • severe weakness
  • collapse or near-collapse
  • confusion or marked drowsiness
  • vomiting or inability to keep medicines down
  • sudden severe illness or infection

If an emergency hydrocortisone injection has been prescribed, follow the instructions given by your clinical team and seek urgent medical care immediately.

References

Author and review information

Prepared for: aspergillosis.org

Purpose: General information for patients, carers, and non-specialist healthcare professionals

Important note: This article is intended for general education and should not replace individual medical advice from your own clinical team.

by GAtherton

Muscle Cramps in Aspergillosis (Including ABPA and CPA): Causes, Triggers, and What May Help

Last reviewed: March 2026
Audience: Patients, carers, and non-specialist healthcare professionals

Key Points

  • Muscle cramps—especially at night—are commonly reported by people with long-term lung conditions such as allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA).
  • There is usually no single cause; cramps often result from a combination of factors including medications, fatigue, hydration, and electrolyte balance.
  • In CPA, additional factors such as antifungal therapy and kidney function may play an important role.
  • Persistent or worsening cramps should be discussed with a healthcare professional, as some causes are treatable.

Contents

Overview

Muscle cramps are sudden, involuntary contractions of a muscle that can last from seconds to several minutes. Many people describe them as painful tightening or “locking” of the muscle, often affecting the calves, thighs, feet, or hands.

For people living with aspergillosis, including allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA), cramps are frequently discussed in patient communities. They are particularly common at night and may affect sleep and quality of life.

Importantly, while cramps can be uncomfortable and sometimes severe, they are often manageable once contributing factors are identified.

Why do muscle cramps happen?

Muscle cramps occur when the normal signals between nerves and muscles become disrupted. This can be influenced by:

  • Changes in fluid balance (hydration)
  • Electrolyte levels (such as magnesium, potassium, calcium)
  • Muscle fatigue or overuse
  • Nerve sensitivity or irritation

In many cases, more than one of these factors is involved.

How is this linked to aspergillosis and its treatment?

People with aspergillosis may experience additional factors that increase the likelihood of cramps:

  • Medications – some treatments used in lung disease (including antifungals, corticosteroids, and inhalers) may affect muscle function or electrolyte balance
  • Chronic inflammation – ongoing inflammation in the body can affect muscles and nerves
  • Reduced activity or sudden changes in activity – both inactivity and overexertion can trigger cramps
  • Co-existing conditions – such as kidney or hormonal conditions, which can influence electrolyte balance

Because many patients take multiple medications, it can sometimes be difficult to identify a single cause.

Additional considerations in chronic pulmonary aspergillosis (CPA)

People living with chronic pulmonary aspergillosis (CPA) may experience additional factors that increase the likelihood of muscle cramps.

  • Long-term antifungal therapy – medications such as azoles (e.g. itraconazole or voriconazole) can affect electrolyte balance or interact with other medicines
  • Kidney function – the kidneys play a key role in regulating electrolytes, and even mild changes may contribute to cramping
  • Electrolyte imbalance – including magnesium, potassium, and calcium levels, which may fluctuate despite supplementation
  • Medication combinations – multiple treatments may have additive effects on muscles or nerves
  • Fatigue and reduced conditioning – common in chronic lung disease and may increase susceptibility to cramps

These factors mean that cramps in CPA are often multifactorial and may change over time.

Common Contributing Factors

Based on patient reports and clinical understanding, the following are commonly associated with muscle cramps:

  • Physical exertion – especially in physically demanding jobs
  • Age-related muscle changes
  • Dehydration
  • Electrolyte imbalance
  • Medication effects
  • Poor sleep or positioning

Some people also report cramps affecting multiple muscle groups at the same time, which can feel particularly intense.

What May Help Reduce Cramps

While individual responses vary, some general approaches that people find helpful include:

  • Maintaining hydration
  • Gentle stretching before bed
  • Regular, moderate activity
  • Medication review with a clinician or pharmacist
  • Balanced nutrition

Important: Supplements such as magnesium are commonly used, but may not be effective for everyone and should be discussed with a healthcare professional—particularly if you have kidney conditions or are taking multiple medications.

When to Seek Medical Advice

You should consider speaking to your GP or specialist team if:

  • Cramps are becoming more frequent or severe
  • They involve multiple muscle groups regularly
  • They are disrupting sleep or daily life
  • You have recently started or changed medications

Seek more urgent medical advice if:

  • Muscle weakness develops
  • There is swelling or redness
  • Dark urine or reduced urine output occurs

Common Questions

Are muscle cramps a symptom of aspergillosis?

They are not a defining symptom but are commonly reported, likely due to a combination of treatment effects and general health factors.

Why do cramps happen at night?

Night-time cramps are common and may relate to fatigue, hydration, and circulation changes during rest.

If I take magnesium, shouldn’t cramps stop?

Not necessarily. Muscle cramps often have multiple causes.

Are cramps more important to report in CPA?

Yes—particularly if you are on long-term antifungal treatment or have kidney-related issues, as these may be relevant.

References & Further Reading

  • National Institute for Health and Care Excellence (NICE) – Muscle cramps guidance
  • UK National Health Service (NHS) – Leg cramps overview
  • General clinical literature on electrolyte balance and muscle function

Author & Review Information

Author: Aspergillosis Patient Education Team
Review status: General educational content aligned with UK clinical practice
Disclaimer: This article is for information only and does not replace medical advice. Always consult your healthcare team regarding symptoms or treatment.

by GAtherton

Aspergillosis Research Update: Week Ending: 30 March 2026

Contents

Key highlights

  • Increasing clarity on influenza-associated pulmonary aspergillosis (IAPA) and ongoing uncertainty around prophylaxis
  • New insights into immune recognition of Aspergillus relevant to vaccine development
  • Evidence that persistent Aspergillus colonisation may worsen bronchiectasis outcomes
  • Early-stage research into drug repurposing strategies
  • Continued reports of complex co-infections in immunocompromised patients

Paper summaries

Incidence and outcomes of influenza-associated pulmonary aspergillosis and the role of antifungal prophylaxis: a structured literature review

Sedik S, Felber D, Schellongowski P, Salzer HJF, Bellmann R, Muhr T, Auer J, Krippl P, Lux M, Zajic P, Werner M, Bauer N, Watzinger N, Mesaric G, Tinawi Y, Dichtl K, Wolfgruber S, Biswas S, Prattes J, [...] Hoenigl M
Critical Care, 26 March 2026
PMID: 41888868

Summary
This structured review examines how often influenza-associated pulmonary aspergillosis occurs, the outcomes associated with it, and whether antifungal prophylaxis has a role in prevention.

Key points

  • IAPA remains a serious complication of influenza in critically ill patients.
  • Mortality appears high, particularly in patients requiring intensive respiratory support.
  • The evidence for antifungal prophylaxis remains inconclusive.
  • Diagnostic uncertainty continues, especially when trying to distinguish colonisation from invasive disease.

Relevance
This is important because it mirrors concerns seen with COVID-19-associated pulmonary aspergillosis and underlines the need for clearer ICU diagnostic and prevention pathways.


Effect of transient versus persistent Aspergillus colonisation on clinical outcomes in bronchiectasis

Michaud A, Jarand J, Thornton CS
ERJ Open Research, 23 March 2026
PMID: 41878279

Summary
This study looks at whether transient and persistent Aspergillus colonisation have different effects on people with bronchiectasis.

Key points

  • Persistent colonisation was associated with worse respiratory outcomes.
  • Patients with persistent colonisation appeared to have more symptoms and exacerbations.
  • Transient colonisation seemed less clinically important.
  • The findings sit outside Allergic Bronchopulmonary Aspergillosis (ABPA), which makes them especially interesting.

Relevance
This is one of the most clinically relevant papers this week for chronic lung disease. It suggests Aspergillus in sputum may not always be an incidental finding, especially if it is repeatedly present.


α-1,3-Glucan-Driven Remodeling of the Conidial Cell Wall in an Aspergillus fumigatus Vaccine Strain Alters Innate Immune Recognition

Singh K, Ankur A, Yarava JR, Fernandes CM, Vascelli G, Sulla A, Zelante T, Del Poeta M, Wang T
Journal of the American Chemical Society, 26 March 2026
PMID: 41883285

Summary
This experimental paper explores how changes in the Aspergillus fumigatus conidial cell wall alter how the innate immune system detects the fungus.

Key points

  • Changes in α-1,3-glucan altered the structure of the fungal cell wall.
  • That remodelling changed how the fungus was recognised by innate immune pathways.
  • The work may help inform future vaccine design or immune-targeted therapies.

Relevance
This is early-stage science rather than immediately practice-changing work, but it improves understanding of how Aspergillus may evade immune recognition and how future preventive strategies could be designed.


Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species

Khan AA, Salama EA, Seleem MN
PLOS One, 25 March 2026
PMID: 41880294

Summary
This laboratory study investigates whether antiretroviral drugs can enhance the antifungal activity of amphotericin B against Aspergillus species.

Key points

  • Some antiretrovirals showed synergistic activity with amphotericin B.
  • The combination improved inhibition of hyphal growth.
  • This raises the possibility of drug repurposing in invasive aspergillosis.

Relevance
This is interesting as a proof-of-concept study. It is not ready for clinical use, but it points toward possible future combination strategies, especially where resistance or toxicity limits current treatment options.


Coexistence of pulmonary aspergillosis and cryptococcosis following treatment for SARS-CoV-2 infection in a kidney transplant recipient: a rare case report and literature review

Hu C, Ying L, Zhan Y, Wang J, Ye J, Lu J, Jin H, Tan X, Gu L, Yao Y, Jiang N
BMC Nephrology, 23 March 2026
PMID: 41872830

Summary
This case report describes a kidney transplant recipient who developed both pulmonary aspergillosis and cryptococcosis after SARS-CoV-2 infection.

Key points

  • Demonstrates the potential for multiple opportunistic fungal infections in highly immunosuppressed patients.
  • Shows how diagnosis can become particularly complex when symptoms and imaging overlap.
  • Reinforces the need for a broad differential diagnosis in transplant recipients and similar high-risk groups.

Relevance
Although a single case, it is a useful reminder that fungal infection in immunocompromised patients may not always be limited to one pathogen, particularly after severe viral infection or intense immunosuppression.


Severe COVID-19 in the Republic of Korea: Epidemiology, Risk Factors, Therapeutics, and Prognostic Models From Nationwide Data

Choi JY
Journal of Korean Medical Science, 23 March 2026
PMID: 41873446

Summary
This review of nationwide Korean data includes discussion of severe COVID-19 complications, including COVID-19-associated pulmonary aspergillosis.

Key points

  • There was a trend toward increased COVID-19-associated pulmonary aspergillosis (CAPA).
  • Risk appeared higher in patients needing the most advanced respiratory support, including ECMO.

Relevance
This reinforces the continuing importance of CAPA internationally and supports ongoing vigilance in critical care settings, especially where viral lung injury and immunomodulatory treatment intersect.

Temporal Trends and Clinical Outcomes of Pediatric Invasive Fungal Diseases: A Ten-Year Retrospective Study from a Tertiary-Care Center in Thailand

Niyomthammarat C, Meesilpavikkai K, Chintanapakdee W, Sophonphan J, Anugualruengkitt S, Puthanakit T, Jantarabenjakul W
Research Square, 23 March 2026
Status: Preprint v1

Summary
This ten-year retrospective study of paediatric invasive fungal disease includes a substantial number of invasive aspergillosis episodes.

Key points

  • Invasive aspergillosis was one of the major fungal disease categories identified.
  • Outcomes varied according to underlying condition and likely also the speed of diagnosis and treatment.

Relevance
This paper does not currently have a PubMed listing because it is a preprint rather than a final indexed journal paper, but it still offers useful background on paediatric invasive fungal disease burden.

Initial presentation, etiology and risk factors for adverse outcomes in infection-associated plastic bronchitis in children

Cao H, Liang D, Huang H, He Q, Wu L
Frontiers in Pediatrics, 28 March 2026
PMCID: PMC13021623

Summary
This retrospective paediatric study is not primarily an aspergillosis paper, but it mentions allergic bronchopulmonary aspergillosis among conditions relevant to plastic bronchitis.

Key points

  • ABPA appears as part of the broader differential diagnosis in children with this presentation.
  • The study mainly concerns airway obstruction and risk factors for poor outcome rather than aspergillosis itself.

Relevance
This has limited direct relevance to most aspergillosis readers, but it is a useful contextual reminder that Aspergillus-related disease can form part of wider airway pathology discussions.

Note: I have not added a PubMed link here because no PMID was supplied. If you want, I can convert this heading to a Europe PMC or PMC link instead.


Aspergillus deflectus-associated disseminated invasive aspergillosis in a German Shepherd dog with discospondylitis: first isolation in Europe

Gernone F, Uva A, Aresu L, Bonfanti U, Ricciardi M, Miglianti M, Barrs VR
Veterinary Research Communications, 25 March 2026
PMID: 41880044

Summary
This veterinary case report documents disseminated invasive aspergillosis caused by Aspergillus deflectus in a German Shepherd dog, reported as the first isolation in Europe.

Key points

  • Expands awareness of the range of Aspergillus species capable of causing invasive disease.
  • Shows how invasive aspergillosis can present as a disseminated multisystem infection.

Relevance
This is not directly about human disease, but it contributes to the wider ecological and pathogenic picture of Aspergillus species.

Overall themes this week

  1. Colonisation versus disease remains a major question.
    Persistent Aspergillus colonisation may be clinically important in bronchiectasis and should not automatically be dismissed.
  2. Severe viral infection remains a major trigger for invasive aspergillosis.
    Both influenza and COVID-19 continue to feature strongly in the literature.
  3. Innovation is active but mostly early-stage.
    Vaccine science, immune recognition work, and drug repurposing studies are all progressing, but none are ready to change routine care yet.
  4. Complex patients are at risk of complex fungal disease.
    Transplant recipients and critically ill patients remain especially vulnerable to difficult-to-diagnose opportunistic infections.

What this means for patients

  • Finding Aspergillus repeatedly in samples may sometimes matter more than a single isolated result.
  • Severe viral illness can increase the risk of serious fungal complications in some people.
  • Researchers are exploring better ways to prevent and treat aspergillosis, but most of these approaches are still under investigation.
  • People with weakened immune systems remain at greatest risk of invasive disease.

by GAtherton

Why Headaches Can Occur in Aspergillosis

Last reviewed: March 2026

Key Points

  • Headaches are relatively common in people living with aspergillosis, but they usually have multiple contributing causes.
  • Common causes include sinus involvement, inflammation, sleep disturbance, and medication effects.
  • Antifungal medicines such as itraconazole may improve some symptoms indirectly but can also occasionally cause headaches.
  • Patterns (timing, location, triggers) can help identify likely causes, but headaches are rarely due to one factor alone.
  • New, severe, or unusual headaches should always be assessed by a healthcare professional.

Table of Contents

Overview

Many people living with aspergillosis report headaches at some point during their illness. These headaches can vary in type, severity, and timing, and may be confusing—especially when they change over time or seem linked to treatment.

In most cases, headaches are not caused by a single factor. Instead, they reflect a combination of:

  • local effects (such as sinus pressure)
  • immune system activity
  • medication effects
  • sleep and general health factors

Understanding these different contributors can help make sense of symptoms and support more informed discussions with your clinical team.

Sinus involvement (common cause)

When Aspergillus affects the sinuses (sometimes called fungal sinusitis), this can directly cause headaches.

This happens because:

  • sinus drainage becomes blocked
  • pressure builds up in the sinus cavities
  • the lining of the sinuses becomes inflamed

Typical features:

  • pain or pressure in the forehead, cheeks, or behind the eyes
  • worsening when bending forward
  • a feeling of fullness or congestion

This is one of the most direct ways aspergillosis can lead to headaches.

Inflammation and immune response

Even when the sinuses are not directly involved, the body’s immune response to fungal material can cause systemic effects.

The immune system releases signalling molecules (such as cytokines) that can:

  • increase inflammation
  • affect blood vessels
  • trigger headache pathways

This type of headache can feel similar to a “flu-like” or inflammatory headache.

Allergic-type responses (e.g. ABPA)

In conditions such as Allergic Bronchopulmonary Aspergillosis (ABPA), the immune system reacts strongly to Aspergillus.

This may involve:

  • allergic pathways
  • histamine and related mediators
  • ongoing airway inflammation

Possible symptoms:

  • head pressure or discomfort
  • fluctuating headaches
  • a “foggy” or unwell feeling

These headaches are often less clearly localised than sinus-related pain.

Medication effects

Some treatments used in aspergillosis can contribute to headaches.

Antifungal medications (e.g. itraconazole):

  • headache is a recognised side effect in some people
  • effects vary between individuals

Steroids (if prescribed):

  • can affect sleep and mood
  • may influence blood pressure
  • can indirectly contribute to headaches

Medication effects can sometimes overlap with disease-related symptoms, making patterns harder to interpret.

Sleep disturbance and night symptoms

Sleep disruption is common in chronic lung conditions.

Possible contributors include:

  • night-time coughing
  • breathlessness
  • discomfort or anxiety

Poor sleep can lead to:

  • morning headaches
  • increased sensitivity to pain
  • fatigue-related headaches

Breathing and oxygen levels

In some people with more advanced lung involvement:

  • oxygen levels may be slightly reduced
  • breathing effort may increase

This can contribute to:

  • morning headaches
  • fatigue and cognitive symptoms

Not all patients experience this, but it is an important factor in some cases.

General health factors

Headaches can also be influenced by general aspects of living with a long-term condition:

  • dehydration
  • fatigue
  • reduced activity levels
  • stress or anxiety

These factors can contribute to tension-type headaches or make other headache types more noticeable.

Understanding headache patterns

Looking at patterns can sometimes help identify likely contributors.

  • Facial pressure worse on bending: may suggest sinus involvement
  • Early morning headaches: may relate to sleep or breathing patterns
  • Fluctuating or “wave-like” symptoms: may reflect inflammation or immune activity
  • New headaches after starting medication: may be treatment-related

However, these are general observations only and do not replace clinical assessment.

Headaches in Aspergillosis: Interactive Decision Aid

This tool helps patients and carers think about common patterns that can contribute to headaches in aspergillosis. It does not diagnose the cause of a headache.

It is designed to support discussion with a healthcare professional and highlight possible contributors such as sinus involvement, inflammation, medication effects, sleep disturbance, and breathing-related factors.

Important: This tool is for general information only. It cannot determine the cause of an individual’s symptoms and does not replace medical advice. If you are concerned about headaches or changes in symptoms, please speak to your healthcare team.

1. Where is the pain mainly felt?



2. When is it most noticeable?



3. What does it feel like?



4. What other features are present?






5. Are there any red flags?



Possible contributors

This panel highlights common patterns only. It is not a diagnosis and does not replace medical assessment.

These are possible patterns only and are not a diagnosis.
This tool is intended to support discussion and reflection. If your headaches are new, worsening, or concerning, speak to your healthcare team.
Select your answers and click Show possible contributors.

Common questions

Are headaches a recognised symptom of aspergillosis?

They can occur, but are usually indirect and caused by associated factors such as sinus disease or inflammation.

Can antifungal treatment improve headaches?

In some cases, yes—if symptoms are linked to fungal-related inflammation. However, antifungals can also occasionally cause headaches as a side effect.

Are “histamine-type” headaches part of aspergillosis?

Some patients describe symptoms in this way, but the underlying mechanism is often more complex than histamine alone.

Why do my headaches change over time?

This is common and may reflect changes in inflammation, treatment, sleep, or overall health.

When to seek medical advice

You should seek medical advice if you experience:

  • new or unusually severe headaches
  • headaches that are worsening over time
  • neurological symptoms (e.g. vision changes, weakness, confusion)
  • fever, neck stiffness, or other concerning symptoms

If you are unsure whether your headaches are related to aspergillosis, treatment, or another cause, it is important to discuss this with your healthcare team.

Summary

Headaches in people with aspergillosis are usually caused by a combination of factors rather than a single issue.

The most common contributors include:

  • sinus involvement
  • immune and inflammatory responses
  • sleep disturbance
  • medication effects

Understanding patterns and changes over time can be helpful, but medical assessment is important if symptoms are new, severe, or concerning.

Author and review

Prepared for: aspergillosis.org

Audience: Patients and non-specialist readers

Important: This article is for general information only and does not replace individual medical advice.

References

  1. Patterson TF et al. (2016). Practice Guidelines for the Diagnosis and Management of Aspergillosis.
    PMID: 27365388
  2. Denning DW et al. (2016). Chronic pulmonary aspergillosis guidelines.
    PMID: 26699723
  3. Chakrabarti A et al. (2009). Fungal sinusitis: a categorization and definitional schema.
    PMID: 19522756

by GAtherton

Why Do My “Histamine” Headaches Improve on Itraconazole?

Last reviewed: March 2026

Key Points

  • Itraconazole is an antifungal medicine. It is not an antihistamine.
  • Some people notice that symptoms such as headaches, flushing, or a “histamine-type” feeling become shorter or less intense after starting treatment.
  • This is most likely because itraconazole reduces the fungal burden and the immune response it triggers, rather than blocking histamine directly.
  • Symptoms that happen in the early hours of the morning may also be influenced by the body’s natural day-night rhythm.
  • Changes in symptoms can be helpful clues, but headaches can have more than one cause.

Table of Contents

Overview

Some people taking itraconazole for non-lung or lung forms of aspergillosis notice that symptoms they describe as “histamine-type” symptoms, such as headaches, flushing, pressure, or a general sense of inflammatory overload, become shorter or less severe.

A typical pattern might be:

  • Symptoms start overnight, for example, around 2 am
  • Symptoms previously lasted most of the day
  • Symptoms are now settling much earlier after starting treatment

This can be confusing, especially when the symptoms feel similar to a histamine reaction. The important point is that itraconazole does not work like an antihistamine, but it can reduce symptoms indirectly if a fungal process is contributing to them.

What is itraconazole and how does it work?

Itraconazole is an antifungal medicine used to treat infections caused by fungi such as Aspergillus.

It works by interfering with the production of ergosterol, an essential part of the fungal cell membrane. This weakens the fungus and helps reduce fungal growth and survival in the body.

As the fungal burden falls, the immune system may be less strongly stimulated, and that can lead to a reduction in inflammation-related symptoms.

So although itraconazole does not block histamine directly, it may reduce the underlying trigger that is causing the body to react.

What do people mean by “histamine dump” headaches?

“Histamine dump” is not a formal medical diagnosis, but some patients use it as a practical way of describing symptoms such as:

  • sudden headaches, especially overnight or early in the morning
  • flushing or a feeling of heat
  • pressure in the head or sinuses
  • a sense of being “wired”, agitated, or unwell

These symptoms may involve histamine, but they can also reflect broader inflammation, immune activation, mast cell activity, or other signalling chemicals in the body.

Why might symptoms improve on itraconazole?

If itraconazole is helping, it is most likely doing so indirectly. There are several possible reasons for this.

1. Reduced fungal burden

If fungal material in the body is reduced, there may be less for the immune system to react to. That can mean less inflammatory signalling overall.

2. Reduced immune activation

Fungi can stimulate the immune system in ways that lead to inflammation and, in some people, histamine-related symptoms. If antifungal treatment lowers that stimulus, symptoms may become less intense or settle more quickly.

3. Shorter inflammatory response

Some people find that the symptom still begins, but does not “run on” for as long. For example, a headache that used to last from 2am until late afternoon may now settle by 5am.

Why do symptoms often happen at night?

The body has a natural circadian rhythm, a 24-hour cycle that affects hormones, inflammation, sleep, and immune activity.

  • Some inflammatory signals can be more noticeable overnight
  • Cortisol rises in the early morning, and helps suppress inflammation

Does this mean histamine is the main problem?

Not necessarily. Symptoms may involve multiple pathways, including immune response to fungi, general inflammation, mast cell activity, and sinus pressure.

Common questions

Does itraconazole act like an antihistamine?

No. It does not block histamine receptors.

Why are my symptoms improving but not gone?

This is common and may reflect partial control of the underlying trigger.

Does this prove Aspergillus is the cause?

No. It suggests a possible link but does not confirm causation.

Will symptoms continue to improve?

Possibly, but responses vary between individuals.

When to seek medical advice

  • new or severe headaches
  • neurological symptoms (vision, speech, balance)
  • worsening or persistent symptoms
  • concerns about medication side effects

Summary

Itraconazole does not directly affect histamine but may reduce symptoms by lowering fungal burden and immune activation.

Author and review

Prepared for: aspergillosis.org

Audience: Patients and non-specialist readers

Important: This does not replace individual medical advice.

References

  1. Patterson TF, Thompson GR 3rd, Denning DW, et al. (2016).
    Practice Guidelines for the Diagnosis and Management of Aspergillosis.
    View on PubMed (PMID: 27365388)
  2. Denning DW et al. (2016).
    Chronic pulmonary aspergillosis guidelines.
    View on PubMed (PMID: 26699723)
  3. Barnes PJ, Adcock IM (2009).
    Circadian rhythm in airway disease.
    View on PubMed (PMID: 19336589)
  4. Stone KD et al. (2010).
    IgE, mast cells, and eosinophils.
    View on PubMed (PMID: 20176269)

by GAtherton

Aspergillosis in Pets: A Practical Guide for Owners

Last reviewed: March 2026

Key Points

  • Aspergillosis is an environmental fungal infection, not contagious between pets or people.
  • Dogs are most commonly affected, particularly in the nose and sinuses.
  • Risk increases with exposure to disturbed soil, compost, and decaying plant material.
  • Different animals are affected in different ways depending on behaviour and anatomy.
  • Early recognition and veterinary treatment usually lead to good outcomes.

Table of Contents

What is aspergillosis?

Aspergillosis is caused by Aspergillus, a group of moulds commonly found in soil, compost, and decaying vegetation. Pets are exposed to these spores regularly in everyday environments.

In dogs, the infection most often affects the nasal passages and sinuses. In other animals, particularly birds, it more commonly affects the lungs.

Important: This is not a contagious disease. It is acquired from the environment.

Which pets are more susceptible?

Dogs

  • Most commonly affected species
  • Higher risk in long-nosed breeds (e.g. German Shepherds, Collies, Greyhounds)
  • Risk increased by sniffing, digging, and outdoor exploration

Cats

  • Less commonly affected
  • Can develop nasal or sinus infection, occasionally more invasive

Birds

  • Most sensitive species
  • Infection usually affects the lungs and air sacs
  • Risk increased in dusty or poorly ventilated environments

Other animals

  • Farm animals (e.g. horses) can be affected, but this is uncommon
  • Small pets (rabbits, rodents) are rarely affected

Do risks differ between animals?

Yes. The same environment can pose different risks depending on how an animal interacts with it.

  • Dogs: close to the ground → inhale spores while sniffing or digging
  • Cats: roaming behaviour → exposure in gardens, sheds, and debris
  • Birds: airborne exposure → sensitive lungs affected in enclosed or dusty spaces

Key insight: The common factor is exposure to fungal spores, but the route of exposure differs between species.

Warning signs to look out for

Dogs (most common presentation)

  • Persistent nasal discharge (often one-sided)
  • Sneezing
  • Nosebleeds
  • Pain around the nose

More advanced signs

  • Swelling around the nose or eyes
  • Loss of pigment or ulceration on the nose
  • Lethargy or reduced appetite

Birds

  • Breathing difficulty
  • Lethargy
  • Reduced appetite

Key message: Persistent symptoms—especially nasal discharge or breathing problems—should always be checked by a vet.

Environmental risks: what to avoid

Aspergillus grows in decaying organic material. Risk increases when this material is disturbed and spores become airborne.

Higher-risk environments

  • Disturbed soil (construction or garden clearance)
  • Rotting leaves, wood, or plant debris
  • Compost heaps and garden waste
  • Bark chippings or mulch
  • Stored hay, straw, or grain
  • Dusty sheds, barns, or enclosed spaces

Situations that increase exposure

  • Digging or burrowing
  • Prolonged sniffing in debris-rich areas
  • Dry, windy conditions
  • Poor ventilation (especially for birds)

Common factors across all pets

  • Decaying organic material
  • Disturbance of soil or vegetation
  • Dust and airborne particles
  • Enclosed or poorly ventilated environments

Simple precautions

  • Keep dogs on a lead near disturbed areas
  • Avoid allowing pets to dig in compost or debris
  • Keep bird enclosures clean and well ventilated
  • Allow disturbed sites to settle before use
  • Rinse paws and muzzle after muddy walks

Balanced view: These environments are common and most pets are exposed without becoming ill. The aim is to reduce exposure during higher-risk periods.

Treatment and management

Aspergillosis in dogs is usually treatable and often curable.

Typical treatment

  • Antifungal medication applied directly into the nasal passages under anaesthetic
  • Removal of fungal material (debridement)

Other approaches

  • Oral antifungal medication in selected cases
  • Supportive care (pain relief, monitoring)

Follow-up is important to ensure the infection has fully cleared.

Risk to people and other pets

  • Not contagious between animals or humans
  • Healthy people are at very low risk
  • Higher-risk individuals are those with lung disease or weakened immune systems

When to seek veterinary advice

  • Nasal discharge lasting more than a few days
  • Blood from the nose
  • Persistent sneezing or discomfort
  • Breathing problems (especially in birds)
  • Swelling around the face

Early diagnosis improves outcomes significantly.

Common questions

Can pets catch aspergillosis from people?

No. It is acquired from the environment.

Is a damp home a cause?

Damp environments can contain spores, but most cases—especially in dogs—are linked to outdoor exposure.

Is this common?

It is uncommon overall, but a recognised cause of nasal disease in dogs.

Summary

Aspergillosis is an environmental fungal infection that affects different animals in different ways. Dogs are most commonly affected through sniffing contaminated material, while birds are more sensitive to airborne spores in enclosed spaces. Although exposure is common, illness is uncommon, and simple precautions combined with early veterinary care usually lead to good outcomes.

Author: Aspergillosis Patient Support & Education Team

Review: This information is for general guidance only and does not replace veterinary advice. If you are concerned about your pet, please consult your veterinary surgeon.

by GAtherton

Why Join an Online Support Group if You Have Aspergillosis?

You are not alone with aspergillosis

Join a friendly online support meeting — no pressure, just listen if you prefer.

Many patients find that even attending once helps them feel more reassured, informed, and supported.


View meeting times and book your place

Why Join an Online Support Group if You Have Aspergillosis?

Living with aspergillosis can feel isolating. Many people go for years without meeting another person with the same condition. Family and friends may be supportive, but they may not fully understand what it is like to live with breathlessness, fatigue, treatment side effects, uncertainty, or repeated hospital visits.

That is one reason online support groups can be so valuable. They bring people together who understand, often immediately, many of the challenges that aspergillosis can bring.

Key points

  • Online support groups reduce isolation and help patients feel understood
  • They offer shared experience alongside emotional support
  • They improve confidence and understanding of the condition
  • They help patients feel better prepared for appointments
  • They are flexible — you can simply listen if you prefer

What changes when people join a support group?

Before joining

  • Feeling alone with the condition
  • Uncertainty about symptoms
  • Limited practical advice
  • Low confidence at appointments
  • Worry about the future

After joining

  • Connection with others who understand
  • Better understanding of the condition
  • Practical day-to-day coping ideas
  • More confidence asking questions
  • Feeling more supported and reassured

Why aspergillosis can feel so isolating

Aspergillosis is a relatively rare condition, and many patients never meet someone else with the same diagnosis. Online support groups help bridge that gap by creating a shared space for understanding and connection.

1. You realise you are not alone

Hearing others describe similar symptoms and challenges can be immediately reassuring and reduce feelings of isolation.

2. Shared experience can be deeply reassuring

Support groups provide practical, real-world insight into managing fatigue, pacing, work, and daily life.

3. You may understand your condition better

Listening to others and accessing shared resources helps build confidence and understanding.

4. It can help you feel more confident at appointments

Patients often feel better prepared and more able to ask the right questions.

5. Emotional support matters too

These groups provide encouragement, understanding, and a sense of belonging.

What happens in a typical online support session?

  • Friendly welcome — no pressure to speak
  • Open discussion — share or listen
  • Optional topics — such as fatigue or treatment experiences
  • Flexible participation — camera and microphone optional
  • Safe, moderated space

Many people attend their first session just to listen — and that is completely fine.

What patients often say

“I wish I had joined sooner. Just hearing others talk made a huge difference.”

“I didn’t speak in my first meeting, but it really helped just listening.”

“It helped me understand my condition and feel more confident.”

Thinking of joining?

You can attend once, listen, and decide if it feels helpful. There is no obligation to continue.

View meeting times and book here:

https://aspergillosis.org/support-meetings/

Meetings are held online using Microsoft Teams. You will receive a joining link after booking.

Bottom line

Online support groups offer connection, reassurance, and understanding. They cannot replace medical care, but they can make living with aspergillosis feel more manageable and less lonely.

Please note: These groups are for support and shared experience. They do not replace advice from your own doctor or specialist team.

by GAtherton

Donating Your Body for Medical Research in the UK

Including research that may help conditions such as aspergillosis

This is an uncommon request, but it can be very helpful to researchers. There is no compulsion at all to consider body donation. It is entirely a personal choice. Many people will decide that it is not for them, and that is completely understandable. For those who do wish to explore it, however, body donation can make an important contribution to medical education, training, and research.

What does body donation mean?

In the UK, donating your body means leaving it after death to a medical school or other appropriately licensed institution for anatomical examination, education, training, or research.

You cannot usually donate your body specifically to “aspergillosis research” alone. However, donation may still support work that is highly relevant to people affected by aspergillosis, including:

  • lung disease
  • infection
  • immune responses
  • medical training in complex respiratory illness

The most important point: consent must be given in advance

Under UK law, body donation must be arranged before death. This means:

  • you must give written consent
  • the consent must usually be witnessed
  • your family cannot normally make this decision for you after you die

How to arrange body donation

  1. Choose a medical school
    You need to contact a medical school directly. Most only accept donations from their local area.
  2. Request an information pack
    The school will explain its process, send consent forms, and set out any restrictions.
  3. Complete the consent forms
    Keep copies with your important papers and let your family know your wishes.
  4. Tell your next of kin or executor
    They will usually need to contact the medical school promptly after death.

Important to understand

  • Not every donation can be accepted. Even if you have registered, a medical school may not be able to accept the body in every circumstance.
  • A backup funeral plan is important.
  • Body donation is separate from organ donation. They are different systems and require separate arrangements.

Can I ask for donation to help lung or aspergillosis-related research?

You can certainly explain that your interest is in supporting research and education relevant to lung disease, infection, or aspergillosis. However, you cannot usually guarantee exactly how a donated body will be used. Even so, donation may still support education and research that benefits future patients with complex respiratory and fungal conditions.

Where to start: Human Tissue Authority

The best first step is the Human Tissue Authority (HTA), which provides UK guidance and a way to identify the correct medical school for your postcode.

Examples of medical school body donation pages

Please note: contact details and catchment arrangements can change, so it is wise to confirm current information directly on each medical school’s website.

Final thought

Donating your body for medical education or research is an unusual and deeply personal decision. There is absolutely no obligation to consider it. But for those who do, it can be a generous and lasting way to support future learning, better care, and research that may help people living with serious conditions, including aspergillosis.

Last reviewed: March 2026

by GAtherton

How Inflammation in One Part of the Body Can Affect the Rest of the Body

Last reviewed: 24 March 2026
Audience: Patients, families, and non-specialist clinicians
Author: Aspergillosis.org editorial team

Many people think of inflammation as something that stays in one place: a painful joint, an inflamed lung, an irritated sinus, or a bowel flare. In reality, inflammation is often a whole-body process. Signals released at one site can travel through the blood, nervous system, and immune system, influencing other organs and changing how the body feels and functions overall.

This helps explain why a local health problem can sometimes lead to symptoms that seem much broader, such as fatigue, poor concentration, low mood, loss of appetite, aches, disturbed sleep, or worsening of other long-term conditions.

Key points

  • Inflammation is not always confined to one organ or body part.
  • Inflamed tissues release chemical messengers that can circulate throughout the body.
  • The brain, heart, kidneys, liver, gut, lungs, and immune system all communicate with one another.
  • This “cross-talk” can be helpful in short-term illness, but harmful when inflammation becomes prolonged.
  • Ongoing inflammation is linked with fatigue, brain fog, low mood, cardiovascular strain, and worsening of other chronic diseases.

Table of contents

What is inflammation?

Inflammation is part of the body’s defence system. It is one of the ways the immune system responds to infection, injury, irritation, allergens, or tissue damage. In the short term, inflammation is often helpful. It can help the body fight infection, clear damaged tissue, and begin repair.

But inflammation can also become too strong, too prolonged, or poorly controlled. When that happens, the effects may no longer stay limited to the original problem area.

Why inflammation does not always stay local

When tissue becomes inflamed, immune cells release small signalling proteins called cytokines and other inflammatory mediators. These act like chemical messages. Some stay nearby, but many enter the bloodstream and influence distant organs.

This is why inflammation in one part of the body can sometimes cause:

  • tiredness or exhaustion
  • feeling unwell or “washed out”
  • poor concentration or “brain fog”
  • worsening appetite
  • sleep disruption
  • higher strain on the heart or kidneys
  • worsening of other inflammatory conditions

Researchers increasingly describe this as systemic inflammation or organ cross-talk. In other words, organs do not operate in isolation. They are part of an interconnected network.

How the body communicates during inflammation

1. Chemical messengers in the blood

Inflamed tissues can release cytokines such as interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumour necrosis factor alpha (TNF-α). These may affect blood vessels, metabolism, the brain, the heart, and other immune cells.

These signals are useful during short-term illness, but if they remain elevated they may contribute to chronic symptoms and long-term health effects.

2. Organ-to-organ immune cross-talk

Modern immunology shows that the gut, liver, lungs, brain, heart, kidneys, and bone marrow can influence one another through immune signalling. A problem in one organ may therefore alter immune behaviour somewhere else.

This can be protective, but it can also become part of a vicious circle, especially in chronic disease.

3. Nerve signalling between the body and brain

Inflammation is not communicated only by blood. The nervous system also plays a role. Signals from inflamed tissues can travel through nerves, including the vagus nerve, to the brain. The brain then responds by adjusting immune activity and body-wide stress responses.

This helps explain why inflammation can affect fatigue, mood, motivation, sleep, and mental clarity.

4. Stress, hormones, and metabolism

Inflammation also interacts with the body’s hormonal and metabolic systems. This can influence energy use, blood sugar regulation, muscle strength, and appetite. Over time, chronic inflammation may put extra strain on the cardiovascular and kidney systems.

Common whole-body effects of inflammation

Fatigue

One of the most common effects of inflammation is fatigue. This is not simply feeling sleepy. It can be a profound lack of physical and mental energy. Many chronic inflammatory illnesses are associated with this kind of exhaustion.

Brain fog and mood changes

Inflammatory signals can affect the brain, contributing to reduced concentration, slowed thinking, low motivation, anxiety, or low mood. This does not mean symptoms are “all in the mind”. It means that immune activity can influence brain function.

Heart and blood vessel effects

Inflammation can make blood vessels less healthy over time and may contribute to a higher cardiovascular risk. This is one reason why long-standing inflammatory diseases are often linked to heart and circulatory problems.

Kidney effects

The kidneys are sensitive to inflammatory stress. In some conditions, long-term systemic inflammation can contribute to kidney damage or worsen existing kidney disease. Kidney disease itself can also increase inflammation, creating a two-way relationship.

Muscle weakness and reduced stamina

Ongoing inflammation can alter how muscles use energy and recover after activity. This may contribute to weakness, reduced exercise tolerance, and slower recovery after exertion.

Why this matters in lung disease and aspergillosis

For people with chronic lung conditions, including some forms of aspergillosis, inflammation in the airways or lungs may have effects beyond breathing alone. The lungs are not separate from the rest of the body.

Inflammation in the lungs may contribute to:

  • general fatigue
  • poor stamina
  • sleep disruption
  • brain fog
  • loss of appetite
  • worsening of other conditions

This can be especially relevant for people living with long-term inflammatory lung disease, repeated infections, allergic inflammation, or complex treatment burdens.

It is also one reason why patients sometimes feel that their symptoms are “bigger” than what would be expected from the lungs alone. Often, that experience is real and biologically plausible.

Acute inflammation versus chronic inflammation

Acute inflammation

This is the short-term response seen with infection, injury, or a sudden flare. It may cause fever, pain, swelling, and marked tiredness. Usually, it settles when the trigger is controlled.

Chronic inflammation

This is lower-grade or persistent inflammation that continues over time. It may be driven by chronic infection, immune dysregulation, ongoing tissue damage, obesity, autoimmune disease, long-term lung disease, or other medical problems. Chronic inflammation is often less dramatic but may have broader long-term effects.

What can help?

The right approach depends on the underlying cause. Broadly, management focuses on:

  • identifying and treating the cause of inflammation where possible
  • controlling infections or allergic triggers
  • optimising treatment of the underlying disease
  • supporting sleep, nutrition, and pacing of activity
  • monitoring the effects on other organs when relevant

There is rarely a single quick fix for chronic inflammation. Good management usually means looking at the whole person, not just the inflamed organ.

When to seek medical advice

Please seek medical advice if inflammation-related symptoms are worsening or if you develop:

  • new or severe breathlessness
  • chest pain
  • confusion or marked drowsiness
  • new swelling, reduced urine output, or signs of dehydration
  • persistent fevers
  • rapid decline in energy, mobility, or daily functioning

If symptoms are sudden, severe, or alarming, seek urgent medical help.

Common questions

Does inflammation always damage the whole body?

No. Short-term, controlled inflammation is a normal and useful response. Problems are more likely when inflammation is severe, repeated, or persistent.

Can one inflamed organ affect another?

Yes. There is now strong evidence that organs influence one another through immune, vascular, metabolic, and nerve-based pathways.

Can inflammation cause fatigue even if blood tests are not dramatically abnormal?

Yes. Symptoms and blood markers do not always match perfectly. Some people experience substantial fatigue and other systemic symptoms even when routine blood tests are only mildly abnormal or intermittently raised.

Is this relevant to chronic lung disease?

Yes. Lung inflammation can have effects that go beyond breathing, including fatigue, reduced stamina, and wider body effects.

References

  1. Dou J, et al. The Interplay of Cross-Organ Immune Regulation in Inflammation and Cancer. MedComm. 2025.
  2. Jin H, Li M, et al. A body–brain circuit that regulates body inflammatory responses. Nature. 2024.
  3. Katkenov N, et al. Systematic Review on the Role of IL-6 and IL-1β in Cardiovascular Diseases. Journal of Cardiovascular Development and Disease. 2024.
  4. Nowak KL, et al. Targeting Inflammation in CKD. Current Opinion in Nephrology and Hypertension. 2025.
  5. Paganin W, et al. Inflammatory biomarkers in depression: a scoping review. 2024.
  6. Mehta NN, et al. IL-6 and Cardiovascular Risk: A Narrative Review. 2024.
  7. Che H, et al. Organ cross-talk: molecular mechanisms, biological functions and therapeutic opportunities. 2026.

Disclaimer: This article is for general information and education. It is not a substitute for personalised medical advice. If you are worried about worsening symptoms, new symptoms, or the effect of inflammation on your health, speak to your clinical team.

by GAtherton